Quantcast

University of Glasgow Becomes a Member of GeneGo’s MetaMiner Stem Cell Partnership Program

January 27, 2009

ST. JOSEPH, Mich., Jan. 27 /PRNewswire/ — GeneGo, Inc., the leading systems biology tools company, announced today that Professor Nicol Keith of the University of Glasgow will join the MetaMiner Stem Cell Partnership Program. The goal of the program is to develop a series of blueprint pathway maps for Adult, Embryonic, Fetal, Fibroblasts, Hematopoietic, Mesenchymal, Multipotent, Neoplastic, Pluripotent and Totipotent stem cells.

“We feel that it is important to support such an initiative as there is a lot of stem cell information in the literature but no one has brought it all together in a set of comprehensive pathway maps,” said Nicol Keith, Professor of Molecular Oncology. “This initiative will allow researchers to have more of a global perspective and allows newcomers to the field to get up to speed quickly.”

“Professor Nicol Keith, of the University of Glasgow in Scotland is world renowned for his pioneering work in cellular immortality and we are pleased to have him on our team,” said Julie Bryant, GeneGo’s VP of Business Development. “We have a lot of experience at building pathway maps and we plan to have 10 types of stem cell pathway maps completed in 24 months.”

About GeneGo, Inc.

GeneGo, Inc. develops systems biology technology such as compound based pathway analysis, cheminformatics & bioinformatics software for life science research. The original computational MetaDiscovery(TM) platform allows an integration and expert analysis of different kinds of experimental data (mRNA expression, proteomics, metabolomics, microRNA assays and other phenotypic data) and relevant bioactive chemistry (metabolites, drugs, other xenobiotics) within the framework of curated biological pathways and networks. GeneGo’s flagship product, MetaCore 5.2(TM), assists pharmaceutical scientists in the areas of target selection and validation, data mining in biology, identification of biomarkers for disease states and toxicology. The second product, MetaDrug 5.2(TM) is designed for prediction of human metabolism, toxicity and biological effects for novel small molecules compounds. MetaBase(TM) represents the knowledge base for MetaCore.

For more information, please visit the company’s web site at www.genego.com.

SOURCE GeneGo, Inc.


Source: newswire



comments powered by Disqus